Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to magnetic relaxometry. The company has collaboration agreement with Wayne State University to develop optimised MRI sequences which is in Phase 2 study of for the MagSense imaging agent. Imagion Biosystems Limited was incorporated in 2016 and is based in Melbourne, Australia.
Frequently asked questions
What sector does Imagion Biosystems Limited (IBXXF) operate in?
Imagion Biosystems Limited belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is Imagion Biosystems Limited (IBXXF) current stock price?
As of the latest data, Imagion Biosystems Limited stock price is $0.00, with a previous close of $0.00.
What is Imagion Biosystems Limited (IBXXF) current market capitalization?
Imagion Biosystems Limited market cap is approximately 3.20 million.
What is Imagion Biosystems Limited (IBXXF) Earnings Per Share (EPS)?
The trailing EPS is -$0.01.
What is Imagion Biosystems Limited (IBXXF) EBITDA?
Imagion Biosystems Limited EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.26 million.
Does Imagion Biosystems Limited (IBXXF) pay dividends?
No. Imagion Biosystems Limited does not pay a dividend.
What is Imagion Biosystems Limited (IBXXF) beta (volatility) score?
Imagion Biosystems Limited has a beta of -0.187, indicating lower volatility than the overall market.
